Why Iambic Therapeutics, Inc. (IAM) stock rose 8.9% on Tuesday, November 10, 2026

Iambic Therapeutics, Inc. (IAM) traded at $14.57 as of 11:31 AM ET, up 8.89% on Tuesday, November 10, 2026, on volume of 612,207 shares (0.7× its 3-month average); market value about $700.0M.

What happened: primary sources

Events Nexqual found for IAM on Tuesday, November 10, 2026 or the trading day before (November 9, 2026):

• Nov 10, 2026: Jefferies: Initiated, Buy, price target $35
• Nov 9, 2026: JP Morgan: Initiated, Overweight, price target $22
• Nov 9, 2026: Citigroup: Initiated, Buy, price target $22
• Nov 9, 2026: B of A Securities: Initiated, Buy, price target $30

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on IAM

IAM stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 10, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 10, 2026 at 16:31 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 10, 2026 at 16:31 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt